Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

babyADE ointment

This article was originally published in The Tan Sheet

Executive Summary

E. Fougera & Co., which makes ointments and ophthalmics for the institutional market, continues its foray into the OTC arena with launch of babyADE A&D + Vitamin E diaper rash ointment. Fougera hopes addition of vitamin E to its standard A&D ointment will "attract health aware parents" and "allow mothers to continue using the diaper rash ointment they were introduced to in the hospital after they go home." Hitting independent drugstore shelves now, babyADE is available in 2 oz. tubes for $3.99-$4.99, 4 oz. tubes for $5.49-$6.99. Firm notes "deals are imminent" to launch ointment in two major national drug chains, with national distribution expected by early 2003...

You may also be interested in...



E. Fougera OTCs

Consumer Products Division will introduce three new OTC products in first aid, athlete's foot areas by mid-2003, company says. Three products will not be Rx switches, but Fougera is "considering additional original developments, transfers from the main line and Rx-to-OTC switch candidates" in the future. Two of newly created division's three original products - HydroZone Plus 1% (hydrocortisone lotion) and babyADE A&D + vitamin E diaper rash ointment - were "an extension of Fougera's Rx experience," firm notes (1"The Tan Sheet" June 3, 2002, In Brief)...

The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy

ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.

US FDA’s 2020 Approvals: A Deep Pipeline, And More Of The Expected

Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).

Topics

UsernamePublicRestriction

Register

PS094077

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel